rosiglitazone has been researched along with Cognition Disorders in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Areosa Sastre, A; González-Colaço Harmand, M; Martínez, G; Vernooij, RW | 1 |
| Craig, A; Issberner, J; Parvez, F | 1 |
| An, P; Chang, L; Chen, X; Guan, Q; Mody, I; Wang, C; Wang, Q; Wei, X; Xu, S; Zhang, J; Zheng, B; Zhou, W | 1 |
| Dong, W; Ji, ZJ; Ma, LN; Meng, XH; Sheng, SL; Wang, HJ; Wang, R; Xu, BL; Zhao, ZW | 1 |
| Abdel-Rahman, E; Ahuja, M; Amin, AT; Amin, RH; Bagasrawala, I; Dhanasekaran, M; Kariharan, T; Nanayakkara, G; Parameshwaran, K; Suppiramaniam, V | 1 |
| Chen, K; Shen, X; Zhao, Y | 1 |
| Changotra, H; Mehta, V; Patel, SS; Udayabanu, M | 1 |
| Chen, L; Chen, T; Li, G; Li, L; Liu, G; Sha, S; Wang, C; Wu, C; Zhou, L | 1 |
| Bains, C; Barrett, SJ; Hosford, D; Irizarry, MC; Lai, RY; Laroche, JP; Maher-Edwards, G; Webb, DJ; Weil, JG | 1 |
| GuiLian, Z; HaiQin, W; Hong, S; HuQing, W; Li, Y; Ru, Z; ShuQin, Z; Xin, Y; Yun, D | 1 |
| Domínguez, RO; González, SE; Marschoff, ER; Repetto, MG; Serra, JA | 1 |
| Fan, X; Freudenreich, O; Goff, D; Henderson, DC; Liu, D; Wang, J; Yi, Z | 1 |
| Asthana, S; Baker, LD; Cholerton, BA; Cook, DG; Craft, S; Fishel, MA; Green, PS; Kahn, SE; Keeling, ML; Kulstad, JJ; Plymate, SR; Reger, MA; Watson, GS | 1 |
| Barry, PJ; Gallagher, P; Ryan, C | 1 |
3 review(s) available for rosiglitazone and Cognition Disorders
| Article | Year |
|---|---|
Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia.
Topics: Carbamates; Cause of Death; Cognition Disorders; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Memory Disorders; Metformin; Piperidines; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2017 |
A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Insulin; Insulin Resistance; Metformin; Mice; Mice, Transgenic; Phosphorylation; Pioglitazone; Rosiglitazone; tau Proteins | 2019 |
Inappropriate prescribing in geriatric patients.
Topics: Accidental Falls; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biotransformation; Cognition Disorders; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Mobility Limitation; Pharmacokinetics; Psychotropic Drugs; Risk Factors; Rosiglitazone; Sleep Wake Disorders; Thiazolidinediones; Treatment Outcome | 2008 |
3 trial(s) available for rosiglitazone and Cognition Disorders
| Article | Year |
|---|---|
Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Neuropsychological Tests; Predictive Value of Tests; Prospective Studies; Risk Factors; Rosiglitazone; Severity of Illness Index; Thiazolidinediones; Vasodilator Agents | 2008 |
Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognition; Cognition Disorders; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Neuropsychological Tests; Pilot Projects; PPAR gamma; Rosiglitazone; Schizophrenia; Thiazolidinediones; Treatment Outcome | 2012 |
Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Cognition Disorders; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mental Recall; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Outcome Assessment, Health Care; Pilot Projects; PPAR gamma; Retention, Psychology; Rosiglitazone; Thiazolidinediones | 2005 |
8 other study(ies) available for rosiglitazone and Cognition Disorders
| Article | Year |
|---|---|
Rosiglitazone prevents the memory deficits induced by amyloid-beta oligomers via inhibition of inflammatory responses.
Topics: Amyloid beta-Peptides; Animals; Cognition Disorders; Hippocampus; Inflammation Mediators; Interferon-gamma; Interleukin-1beta; Long-Term Potentiation; Male; Maze Learning; Memory Disorders; Microglia; Motor Activity; Neuroprotective Agents; Peptide Fragments; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2014 |
Effects of analog P165 of amyloid precursor protein 5-mer peptide on learning, memory and brain insulin receptors in the rat model of cognitive decline.
Topics: Amyloid beta-Protein Precursor; Animals; Brain; Cognition Disorders; Disease Models, Animal; Hypoglycemic Agents; Insulin; Male; Maze Learning; Memory; Peptide Fragments; Rats; Rats, Sprague-Dawley; Receptor, Insulin; Rosiglitazone; Signal Transduction; Streptozocin; Thiazolidinediones | 2014 |
Central activation of PPAR-gamma ameliorates diabetes induced cognitive dysfunction and improves BDNF expression.
Topics: Administration, Oral; Animals; Brain-Derived Neurotrophic Factor; Cognition Disorders; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression; Hippocampus; Hypoglycemic Agents; Injections, Intraventricular; Insulin Resistance; Male; Memory; Mice, Inbred C57BL; Molecular Targeted Therapy; Neuronal Plasticity; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2015 |
Environmental Enrichment Attenuated Sevoflurane-Induced Neurotoxicity through the PPAR-γ Signaling Pathway.
Topics: Animals; Apoptosis; Cognition Disorders; Down-Regulation; Environment; Male; Memory Disorders; Methyl Ethers; Mice, Inbred C57BL; Neurogenesis; Neurons; Neurotoxicity Syndromes; PPAR gamma; Rosiglitazone; Sevoflurane; Signal Transduction; Thiazolidinediones | 2015 |
Depression mediates impaired glucose tolerance and cognitive dysfunction: A neuromodulatory role of rosiglitazone.
Topics: Animals; Behavior, Animal; Blood Glucose; Cognition Disorders; Depression; Disease Models, Animal; Hippocampus; Hypoglycemic Agents; Insulin; Male; Mice; Rosiglitazone; Stress, Psychological; Thiazolidinediones | 2016 |
Activation of PPARγ Ameliorates Spatial Cognitive Deficits through Restoring Expression of AMPA Receptors in Seipin Knock-Out Mice.
Topics: Animals; Cognition Disorders; CREB-Binding Protein; Disease Models, Animal; Enzyme Inhibitors; Gene Expression Regulation; GTP-Binding Protein gamma Subunits; Heterotrimeric GTP-Binding Proteins; Hippocampus; In Vitro Techniques; Long-Term Potentiation; Male; Maze Learning; Mice; Mice, Knockout; Patch-Clamp Techniques; PPAR gamma; Receptors, AMPA; Rosiglitazone; Spatial Behavior; Swimming; Thiazolidinediones | 2016 |
The PPARγ agonist rosiglitazone prevents cognitive impairment by inhibiting astrocyte activation and oxidative stress following pilocarpine-induced status epilepticus.
Topics: Analysis of Variance; Animals; Astrocytes; Benzamides; Cell Count; Cognition Disorders; Disease Models, Animal; Glial Fibrillary Acidic Protein; Glutathione; Glutathione Disulfide; Hippocampus; Lithium Chloride; Male; Maze Learning; Oxidative Stress; Pilocarpine; PPAR gamma; Pyridines; Rats; Rats, Sprague-Dawley; Rosiglitazone; Status Epilepticus; Systole; Thiazolidinediones | 2012 |
Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients.
Topics: Aged; Alzheimer Disease; Argentina; Cognition Disorders; Diabetes Mellitus, Type 2; Disease Progression; Female; Geriatric Assessment; Hippocampus; Humans; Hypoglycemic Agents; Insulin; Longitudinal Studies; Male; Neuropsychological Tests; Oxidative Stress; Pilot Projects; Psychiatric Status Rating Scales; Rosiglitazone; Severity of Illness Index; Thiazolidinediones | 2012 |